Utah Medical Products
UTMD
79 hedge funds and large institutions have $260M invested in Utah Medical Products in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 23 increasing their positions, 31 reducing their positions, and 3 closing their positions.
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
10% more funds holding
Funds holding: 72 → 79 (+7)
8% more capital invested
Capital invested by funds: $241M → $260M (+$18.8M)
0.04% more ownership
Funds ownership: 71.28% → 71.33% (+0.04%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
26% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$6.25M |
| 2 |
QC
Quadrature Capital
London,
United Kingdom
|
+$662K |
| 3 |
Two Sigma Advisers
New York
|
+$367K |
| 4 |
GC
Globeflex Capital
San Diego,
California
|
+$344K |
| 5 |
Two Sigma Investments
New York
|
+$296K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.97M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.67M |
| 3 |
BIP
Brandes Investment Partners
La Jolla,
California
|
-$857K |
| 4 |
Bank of New York Mellon
New York
|
-$800K |
| 5 |
Renaissance Technologies
New York
|
-$727K |
UTMD Hedge Fund Activity: Q4 2021 in Review
79 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Utah Medical Products (UTMD) for Q4 2021, worth a combined $260M — up 7.8% from $241M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new UTMD positions and 3 closed out — a net gain of 7 holders — while 23 added to existing stakes and 31 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $6.25M. The largest seller was Fidelity Investments, cutting an estimated $2.97M.
- 79 institutional investors held Utah Medical Products (UTMD) as of Q4 2021, up from 72 in Q3 2021.
- Funds reported $260M of Utah Medical Products stock for Q4 2021, up 7.8% quarter-over-quarter.
- 10 funds opened new Utah Medical Products positions in Q4 2021 and 3 closed out, a net change of +7 holders.
- The largest Utah Medical Products buyer in Q4 2021 was T. Rowe Price Associates, an estimated $6.25M added.
- The largest Utah Medical Products seller in Q4 2021 was Fidelity Investments, an estimated $2.97M sold.
Based on aggregated 13F filings for Q4 2021.